The Antiangiogenic Therapy in Ovarian Cancer

Loizzi Vera*,1, Cicinelli Ettore1, Del Vecchio Vittoria1, Naglieri Emanuele2, Ranieri Girolamo3 and Cormio Gennaro1,2

1Department of Biomedical Sciences and Human Oncology, University of Bari, Italy
2Gynecologic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
3Interventional and Medical Oncology Unit, IRCCS Istituto, Tumori Giovanni Paolo II, Bari, Italy

Received: May 21, 2018; Published: May 29, 2018

*Corresponding author: Vera Loizzi, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy, Piazza Giulio Cesare 11, Italy

Keywords: Angiogenesis; Vegf; Ovarian Cancer

Mini Review

The standard treatment for epithelial ovarian cancer (EOC) consists of optimal cytoreductive surgery followed by platinum-based chemotherapy [1-2]. Bevacizumab has been approved for the treatment of several tumors such as colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma, epithelial ovarian, fallopian tube, and primary peritoneal cancers. The use of antiangiogenic agent in EOC is based on the results of randomized clinical trials which revealed an improved survival rates with the addition of bevacizumab to standard first-line chemotherapeutic drugs [3-4]. In addition, this benefit has been evaluated in second-line setting both in platinum sensitive and platinum-resistant disease [5-6]. Although standard treatment for EOC is optimal cytoreductive surgery followed by platinum-based chemotherapy [7-8], the role of interval debulking surgery (IDS) after a short course of neoadjuvant chemotherapy (NACT) has also studied and represents an alternative in women unable to undergo upfront complete resection. In fact, no differences in progression-free survival (PFS) were evaluated in EOC patients undergoing IDS compared to those treated with primary debulking surgery. However, few adverse effects and lower mortality rates were observed in the group which included patients treated with IDS [9-10].

Neo Adjuvant Setting

Bevacizumab in the neoadjuvant setting have been studied in few studies [11-12] with controversial results. Therefore its use is not yet recommended in this setting because based on wound complications, gastrointestinal perforations and fistulas, and thromboembolic events [13]. The first study that studied the efficacy and toxicity of preoperative chemotherapy with or without bevacizumab has been the NOVA study. It was a randomized, phase II, multicentric clinical trial. Patients with EOC were randomized to receive 4 cycles of chemotherapy based on carboplatin and paclitaxel with or without bevacizumab. After chemotherapy the patients underwent cytoreductive surgery and postoperative bevacizumab for a total of 22 cycles. No significant response rate was observed even if a higher rate of optimal surgeries in the bevacizumab group was evaluated [12]. The confirmation of the role of bevacizumab in this setting will arrive from another study. In fact the ANTHALYA study is an ongoing, randomized, open-label, phase II trial involving patients with initially unresectable advanced stage ovarian, tubal, or peritoneal carcinoma [14]. Another controversial point is the appropriate interval between bevacizumab administration and subsequent surgery in order to reduce the risk of impaired wound healing/wound dehiscence. There is a consensus to undergo surgery for at least 28 days following their last treatment [15].

First Line Setting

The efficacy of bevacizumab in addition to the standard for first-line treatment based on carboplatin and paclitaxel was showed in two randomized multicenter trials [3-4]. The GOG-218 trial [3] was conducted in patients affected by advanced stage epithelial ovarian, fallopian tube, or peritoneal cancer submitted to first-line chemotherapeutic. The study showed a significantly increase in progression free survival (PFS) in patients receiving bevacizumab plus standard chemotherapy followed by maintenance bevacizumab with respect to patients treated only with standard chemotherapy or without bevacizumab maintenance (14.1 v/s 10.3 and 11.2 months, respectively, p < 0.001). However, these results were not similar for the overall survival (OS), therefore the addition of bevacizumab to standard chemotherapy did not significantly improve the OS. However, a further analysis in patients with only stage IV disease demonstrated improvement in the median OS; it was significantly higher in the group submitted to maintenance bevacizumab versus no maintenance or no bevacizumab. ICON7 trial was the sec-

ond phase III randomized trial that showed similar results [4]. An improved in median PFS was observed in the bevacizumab group (p = 0.0041). The overall response rate was 48% in the chemotherapy-alone group and 67% in the bevacizumab group, respectively (p < 0.0001). However, similarly to the other study, no differences in the OS rate were observed. Only for patients with FIGO stage III sub-optimally debulked or stage IV disease or who had not undergone debulking surgery an OS increase of 9 months was showed. (p = 0.03) [15].

**Recurrent OC Setting**

Platinum-sensitive OC woman is defined who is having a progression-free interval ≥ 6 months from the last platinum chemotherapy. Patients who relapse within this interval are usually treated with platinum-based therapy consisting in combination of carboplatin with paclitaxel or pegylated liposomal doxorubicin (PLD), or gemcitabine [16-18]. Two studies (OCEANS and GOG-213 trials) have studied the role of bevacizumab in the platinum-sensitive recurrent OC setting. The OCEANS is a randomized phase III trial with patients assigned to the standard chemotherapy (intravenous gemcitabine plus carboplatin) with or without bevacizumab (15mg/kg) until disease progression or unacceptable toxicity. The results showed an improved PFS in the bevacizumab group than in the placebo group (p<0.001) [5]. In addition, the overall response rate was higher in the bevacizumab group than in the controls (p<0.0001). However, no improvement in OS was observed. Toxicity in terms of hypertension was higher in the bevacizumab group. For these reasons, bevacizumab has been approved in combination with carboplatin and gemcitabine for patients with a first recurrence of platinum-sensitive EOC or fallopian tube or primary peritoneal cancer who has not received prior therapy with VEGF agents. The second trial is the Gynecologic Oncology Group (GOG)-0213 which has been conducted in patients affected by platinum-sensitive EOC or fallopian tube or peritoneal cancer. Data evaluated an increase in PFS (p < 0.0001) and in OS (p = 0.056) [6].

Platinum-resistant OC woman is defined who is having a progression-free interval < 6 months from the last platinum chemotherapy. Several new cytotoxic drugs have been studied in chemoresistant EOC setting, such as bevacizumab. However, these patients have a poor outcome with a lower tumor response rates. Sehouli et al. have demonstrated that single-agent chemotherapy has been generally recommended based on the increased toxicity with combined therapy without a survival advantage [19]. The only randomized phase III multicenter trial evaluating the efficacy and tolerability of adding bevacizumab to single-agent chemotherapy in patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer is the AURELIA study [20,21]. Patients received single-agent chemotherapy (paclitaxel, PLD, or topotecan) alone or in combination with bevacizumab until disease progression or unacceptable toxicity. The primary endpoint was PFS. The results showed that the median PFS was longer in patients receiving bevacizumab plus chemotherapy. However, no differences in OS were observed. However, to evaluate a definitive profile of efficacy and tolerability of bevacizumab in this setting of patients, the results of ongoing trials investigating bevacizumab alone or in combination with conventional antiblastic agents are necessary.

**References**


